<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01147926</url>
  </required_header>
  <id_info>
    <org_study_id>SPD555-302</org_study_id>
    <secondary_id>M0001-C302</secondary_id>
    <secondary_id>2009-015719-42</secondary_id>
    <nct_id>NCT01147926</nct_id>
  </id_info>
  <brief_title>Evaluation of Prucalopride in Male Subjects With Chronic Constipation.</brief_title>
  <official_title>A 12-week, Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Quality of Life, Safety and Tolerability of Prucalopride in Male Subjects With Chronic Constipation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-centre, randomised, parallel-group, double-blind, placebo-controlled phase
      III trial to evaluate the efficacy of prucalopride versus placebo over 12 weeks of treatment
      in male subjects with chronic constipation.

      Furthermore the safety, tolerability, effect on quality of life and effect on symptoms of
      prucalopride will be assessed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this phase III trial subjects will be screened and enter a 2-week run-in period (or a
      3-week run-in period if the subject is using agents that influence bowel habit) during which
      the presence of constipation will be confirmed [the subject will complete an electronic daily
      diary (e-diary)]. At the start of run-in, all existing laxative medication will be withdrawn
      and subjects will be instructed not to change their diet or lifestyle during the trial.
      Subjects will be allowed to take a laxative [Dulcolax (bisacodyl)] as rescue medication
      during the trial, but only if they have not had a bowel movement (BM) for 3 or more
      consecutive days. An enema can only be used after unsuccessful use of Dulcolax (bisacodyl).
      No Dulcolax (bisacodyl) should be taken or enemas used between 48 hours before and 48 hours
      after the first intake of study medication.

      After the run-in subjects will be randomly assigned to placebo or prucalopride in an equal
      ratio (1:1) if the subject fulfils the constipation criteria for inclusion. Randomisation
      will be stratified by country and by the average number of complete bowel movements (CBM)
      during run-in: 0 CBM/week and &gt; 0 CBM/week.

      Adult subjects (i.e. subjects ≥18 to &lt;65 years of age) will take 2 mg prucalopride or
      matching placebo once daily before breakfast during the entire 12-week treatment period.
      Elderly subjects (i.e. subjects ≥65 years of age) will start at a dose of 1 mg prucalopride
      or matching placebo once daily before breakfast. In case of insufficient response, defined as
      an average of &lt;3 spontaneous complete bowel movements (SCBM)/week during the preceding 2
      weeks of treatment (i.e. since the previous visit) at Week 2 or Week 4, the daily dose has to
      be increased to 2 mg (or matching placebo). Once the dose is increased to 2 mg once daily the
      subject will stay on this dose for the remainder of the trial. After Week 4 (Visit 4) no
      changes in dose are allowed anymore.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Percentage of Subjects With an Average of ≥3 Spontaneous Complete Bowel Movements (SCBM) Per Week</measure>
    <time_frame>Over 12 week treatment period</time_frame>
    <description>Spontaneous Bowel Movements defined as a bowel movement that is not preceded within a period of 24 hours by the intake of a laxative agent or by the use of an enema.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With an Average Weekly Frequency of at Least 3 SCBM Per Week and an Increase of ≥ 1 SCBM Per Week for ≥ 75% of the 12-week Treatment Period and ≥ 75% of the Last Third of the 12-week Treatment Period</measure>
    <time_frame>Over 12 week treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With an Increase of at Least 1 SCBM Per Week</measure>
    <time_frame>Over 12 week treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SCBM Per Week</measure>
    <time_frame>Over 12 week treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent SBM With a Consistency of Normal and Hard/Very Hard</measure>
    <time_frame>Over 12 week treatment period</time_frame>
    <description>Consistency measured using the 7-point Bristol scale where 1-2 indicate constipation (=hard/very hard), 3-4 are ideal stools (=normal), and 5-7 tending toward diarrhea.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent SCBM With No Straining and Severe/Very Severe Straining</measure>
    <time_frame>Over 12 week treatment period</time_frame>
    <description>Straining was evaluated on a 5-point scale (0=none, 1=mild, 2=moderate, 3=severe, or 4=very severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent SBM With Sensation of Complete Evacuation</measure>
    <time_frame>Over 12 week treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First SCBM After Investigational Product Intake on Day 1</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bisacodyl Tablets Taken Per Week</measure>
    <time_frame>Over 12 week treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days With Rescue Medication Taken Per Week</measure>
    <time_frame>Over 12 week treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects With an Improvement of ≥ 1 Point on the Patient Assessment of Constipation - Symptom (PAC-SYM) Questionnaire Total Score at Final On Treatment Assessment</measure>
    <time_frame>Over 12 week treatment period</time_frame>
    <description>The PAC-SYM is a validated 12-item questionnaire for the evaluation of severity of symptoms of constipation in subjects with constipation. Items are rated on a 5-point Likert scale: 0=absent, 1=mild, 2=moderate, 3=severe, 4=very severe. Total score ranges from 0 to 48. Lower scores indicate improvement in symptoms. A 1-point improvement in PAC-SYM total score was considered clinically meaningful.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects With an Improvement of ≥ 1 Point on the Patient Assessment of Constipation - Quality of Life (PAC-QOL) Total Score at Final On Treatment Assessment</measure>
    <time_frame>Over 12 week treatment period</time_frame>
    <description>The PAC-QOL is a validated 28-item questionnaire for the evaluation of quality of life in subjects with constipation. Items are rated on a 5-point Likert scale: 0=not at all/none of the time, 1=a little bit/a little bit of the time, 2=moderately/some of the time, 3=quite a bit/most of the time, 4=extremely/all of the time. Total score ranges from 0-112. Lower scores indicate improvement in symptoms. A 1-point improvement in PAC-QOL total score was considered clinically meaningful.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects on the Subject Global Evaluation on Severity of Constipation Score Rating Constipation as Severe to Very Severe at Final On-Treatment Assessment</measure>
    <time_frame>Over 12 week treatment period</time_frame>
    <description>Subject was asked to rate the severity of his constipation using a 5-point Likert scale: 0=absent, 1=mild, 2=moderate, 3=severe, 4=very severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects on the Subject Global Evaluation on Efficacy of Treatment Score Rating Treatment as Quite a Bit to Extremely Effective at Final On-Treatment Assessment</measure>
    <time_frame>Over 12 week treatment period</time_frame>
    <description>The subject was asked to rate his global evaluation of the efficacy of treatment using the following 5-point scale:
0=not at all effective
a little bit effective
moderately effective
quite a bit effective
extremely effective.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">374</enrollment>
  <condition>Male Subjects With Chronic Constipation</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prucalopride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 milligram (mg) or 2 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matched to Prucalopride tablet orally once daily.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prucalopride</intervention_name>
    <description>Prucalopride 2 mg tablet orally once daily for subjects greater than or equal to (≥) 18 to less than (&lt;) 65 years; 1 mg once daily orally for subjects ≥65 years, and in case of insufficient response, increased to 2 mg once daily orally at Week 2 or Week 4.</description>
    <arm_group_label>Prucalopride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is a male out-patient ≥18 years of age (no upper age limit).

          2. Subject has a history of constipation. The subject reports an average of ≤ 2 SBM/week
             that result in a feeling of complete evacuation (SCBM) and one or more of the
             following for at least 6 months before the selection visit:

               1. Very hard (little balls) and/or hard stools for at least a quarter of the stools;

               2. Sensation of incomplete evacuation following for at least a quarter of the
                  stools;

               3. Straining at defecation for at least a quarter of the time. This includes
                  subjects who never have SBMs. The above criteria are only applicable for SBMs,
                  i.e. BMs not preceded within a period of 24 hours by the intake of a laxative
                  agent or by the use of an enema.

          3. Subject agrees to stop his current laxative treatment and is willing to use rescue
             medication according to the rescue rule [Dulcolax® (bisacodyl)/enemas]

          4. Subject's constipation is chronic.

          5. Subject is able and willing to complete the questionnaires (if a validated version in
             the language of the subject is available) and the e-diary.

          6. Subject voluntarily signs the written Informed Consent Form (ICF) in accordance with
             the regional laws/regulations, prior to the first trial-related activity.

          7. Subject is willing to adhere to all trial requirements (amongst others
             colonoscopy/sigmoidoscopy, if required).

        Exclusion Criteria:

          1. Subjects in whom constipation is thought to be drug-induced.

          2. Subjects using any disallowed medication

          3. Subjects suffering from secondary causes of chronic constipation, such as:

             Endocrine disorders, e.g. hypopituitarism, hypothyroidism, hypercalcaemia,
             pseudohypoparathyroidism, pheochromocytoma or glucagon-producing tumours, unless these
             are controlled by appropriate medical therapy. Subjects with insulin-dependent
             diabetes mellitus should always be excluded, also if the subjects are under
             appropriate medical therapy; Metabolic disorders (e.g. porphyria, uraemia,
             hypokalaemia or amyloid neuropathy, unless these are controlled by appropriate medical
             therapy); Neurological disorders (e.g. Parkinson's disease, cerebral tumours,
             cerebrovascular accidents, multiple sclerosis, meningocele, aganglionosis,
             hypoganglionosis, hyperganglionosis, autonomic neuropathy or neuropathy due to
             chemotherapy, spinal cord injury, Chaga's disease, major depression); Surgery.
             Subjects with insulin-dependent diabetes mellitus should always be excluded,
             irrespective of whether the constipation started prior to or after the onset of
             diabetes.

          4. Subjects with a significant history of cancer (i.e. less than a 5-year disease-free
             survival).

          5. Subjects with intestinal perforation or obstruction due to structural or functional
             disorder of the gut wall, obstructive ileus, severe inflammatory conditions of the
             intestinal tract, such as Crohn's disease, and ulcerative colitis and toxic
             megacolon/megarectum. Results of an endoscopy or radiologic bowel evaluation is
             required to rule out polyps, cancer, stricture or other structural or organic disease:

               1. For patients ≤ 50 years: a flexible sigmoidoscopy or colonoscopy after the onset
                  of constipation symptoms and within the previous 5 years;

               2. For patients &gt; 50 years: a flexible sigmoidoscopy /double contrast barium enema
                  or colonoscopy after the onset of constipation symptoms and within the previous 5
                  years.

               3. For subjects, regardless of age, even if results of this test are available
                  within the previous 5 years but if the patient has alarm symptoms such as anemia,
                  weight loss, heme positive stool, or rectal bleeding: a flexible sigmoidoscopy
                  and double contrast barium enema or colonoscopy is needed after the onset of
                  symptoms.

               4. If abnormalities have been detected during the sigmoidoscopy or colonoscopy e.g.,
                  because of polyps, the subject can be included in the trial if the polyps were
                  removed. If clinically indicated, a repeat colonoscopy/sigmoidoscopy needs to be
                  performed at latest within one week after the screening visit. If no barium enema
                  with flexible sigmoidoscopy or a colonoscopic examination has been performed
                  within the period as described above, the assessment is to be scheduled on the
                  screening visit or within the week following screening. When it is clinically
                  indicated that a repeat colonoscopy/sigmoidoscopy is needed to confirm results of
                  a colonoscopy/sigmoidoscopy performed after the screening visit, the subject
                  should be a screen failure.

          6. Subjects with known serious illness: clinically significant cardiac, vascular, liver,
             pulmonary, or psychiatric disorders (as evaluated by the Investigator).

          7. Subjects with any condition that in the opinion of the Investigator would complicate
             or compromise the trial or the well-being of the subject or evidence of clinically
             relevant pathology that could interfere with the trial results or put the subject's
             safety at risk.

          8. Subjects known to have human immunodeficiency virus (HIV) infection or AIDS, hepatitis
             B or hepatitis C.

          9. Subjects with impaired renal function, i.e. serum creatinine concentration &gt;180 μmol/l
             or calculated creatinine clearance ≤30 ml/min, including subjects requiring dialysis.

         10. Subjects with clinically significant abnormalities of haematology, urinalysis, or
             blood chemistry as determined by the Investigator. If the results of the haematology,
             biochemistry or urinalysis tests are not within the laboratory's reference ranges, the
             subject can be included only on the condition that the Investigator judges that the
             deviations are not clinically significant. This should be clearly recorded in the
             electronic Case Report Form (e-CRF).

         11. Subjects with a known history of alcohol or drug abuse in the previous 6 months.

         12. Subjects with lactose intolerance for whom it is expected that low doses of lactose
             can lead to diarrhoea, or a known allergy to ingredients or excipients of the trial
             medication.

         13. Subjects who received an investigational drug in the 30 days preceding the run-in
             period of the trial.

         14. Subjects who previously used prucalopride.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Gastro-Kliniek cvba</name>
      <address>
        <city>Antwerpen 7</city>
        <zip>2018</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires St Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GP / Huisartsenpraktijk De Regenboog</name>
      <address>
        <city>Deurne</city>
        <zip>2100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Sart Tilman</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Wetteren</city>
        <zip>9230</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>4 MHAT</name>
      <address>
        <city>Sofia</city>
        <zip>1000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCBR Czech Republic Brno</name>
      <address>
        <city>Brno</city>
        <zip>60200</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KKN a.s.</name>
      <address>
        <city>Karlovy Vary</city>
        <zip>36001</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCBR Czech Republic Pardubice</name>
      <address>
        <city>Pardubice</city>
        <zip>530 02</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universtiy Hospital Kralovske Vinhorady</name>
      <address>
        <city>Prague 10</city>
        <zip>100 34</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MONSE s.r.o.</name>
      <address>
        <city>Prague</city>
        <zip>118 33</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Slany</name>
      <address>
        <city>Slany</city>
        <zip>274 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlickoustecka nemocnice</name>
      <address>
        <city>Usti nad Orlici</city>
        <zip>562 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krajska Nemocnice T. Bati a.s., Interni oddeleni - klinika IPVZ; Nemocnicni Lekarna</name>
      <address>
        <city>Zlin</city>
        <zip>762 75</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krajska Nemocnice T. Bati a.s.</name>
      <address>
        <city>Zlin</city>
        <zip>762 75</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCBR DK Aalborg</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCBR DK Ballerup</name>
      <address>
        <city>Ballerup</city>
        <zip>2750</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCBR DK Vejle</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARK Clinical Research</name>
      <address>
        <city>Plessis</city>
        <state>Grammoire</state>
        <zip>49124</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU - Hopital Nord, service gastro-enterologie et hepatologie</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARK Clinical Research (Jean XXIII)</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARK Clinical Research (Proust)</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARK Clinical Research - Chanzy</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARK Clinical Research</name>
      <address>
        <city>Avrille</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Avicenne, Centre d'exploitation fonctionnelle et reducation digestive</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Gastroenterologie &amp; INSERM CIC-P 803 - CHU de Dijon</name>
      <address>
        <city>Dijon Cedex</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Edouard Herriot</name>
      <address>
        <city>Lyon cedex 3</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Archet 2- service gastro-enterologie et hepatologie</name>
      <address>
        <city>Nice</city>
        <zip>06002</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pontchaillou - Service des Maladies de l'Appareil Digestif</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet Médical</name>
      <address>
        <city>Thouars</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARK Clinical Research</name>
      <address>
        <city>Vendome</city>
        <zip>41100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>emovis GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10629</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterologie und Hepatologie am Johannisplatz</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fachartzpraxis für Innere Medizin</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65285</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meander Medisch Centrum</name>
      <address>
        <city>Amersfoort</city>
        <zip>3818 ES</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VU Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PT&amp;R / PreCare Trial &amp; Recruitment</name>
      <address>
        <city>Beek</city>
        <zip>6191JW</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Gelderse Vallei</name>
      <address>
        <city>Ede</city>
        <zip>6716 RP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maastricht Universitair medisch Centrum</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ikazia Ziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <zip>3083 AN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabinet Lekarski Janusz Rudziński</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-681</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut Medycyny Wsi im. Witolda Chodźki - Zaklad Endoskopowych Badań Kliniczncyh</name>
      <address>
        <city>Lublin</city>
        <zip>20-950</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie</name>
      <address>
        <city>Lublin</city>
        <zip>20-954</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endoskopia Sp. z o.o.</name>
      <address>
        <city>Sopot</city>
        <zip>81-756</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indywidualna Specjalistyczna Praktyka Lekarska w Dziedzinie Chirurgii Ogólnej i Gastroenterologii</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Przychodnia Polskiej Fundacji Gastroenterologii Filia Nr 1 NZOZ</name>
      <address>
        <city>Warszawa</city>
        <zip>02-653</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Vivamed</name>
      <address>
        <city>Warszawa</city>
        <zip>03-580</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMI Dr. Lenghel Augustin</name>
      <address>
        <city>Oradea</city>
        <state>Bihor</state>
        <zip>410163</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrul Medical Valahia SRL</name>
      <address>
        <city>Ploiesti</city>
        <state>Prahova</state>
        <zip>100410</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Universitar de Urgenta Militar Central &quot;Dr. Carol Davila&quot;</name>
      <address>
        <city>Bucuresti</city>
        <state>Sector 1</state>
        <zip>010825</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Quantum Medical Center SRL</name>
      <address>
        <city>Bucuresti</city>
        <state>Sector 1</state>
        <zip>011426</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endocenter Medicina Integrativa SRL</name>
      <address>
        <city>Bucuresti</city>
        <state>Sector 2</state>
        <zip>021978</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Cabinet Medical Dr. Blaj Stefan SRL</name>
      <address>
        <city>Bucuresti,</city>
        <state>Sector 5</state>
        <zip>40101</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Mediclass Sananova SRL</name>
      <address>
        <city>Bucuresti</city>
        <state>Sector 5</state>
        <zip>050524</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrul Medical Humanitas</name>
      <address>
        <city>Bucuresti,</city>
        <state>Sector 6</state>
        <zip>062272</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrul Medical Tuculanu SRL</name>
      <address>
        <city>Timisoara</city>
        <state>Timis</state>
        <zip>300158</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrul Medical Sana</name>
      <address>
        <city>Bucuresti</city>
        <zip>11025</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean Cluj,Clinica Medicala I</name>
      <address>
        <city>Cluj</city>
        <zip>400006</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastromedica SRL</name>
      <address>
        <city>Iasi</city>
        <zip>700506</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet Medical Dr. Lokos Barna-Csaba</name>
      <address>
        <city>Judetul Harghita</city>
        <zip>530174</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean de Urgenta Sibiu</name>
      <address>
        <city>Sibiu</city>
        <zip>550245</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMI de Gastroenterologie Dobru Daniela</name>
      <address>
        <city>Targu-Mures</city>
        <zip>540130</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinic Algomed SRL</name>
      <address>
        <city>Timisoara</city>
        <zip>300002</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oldfield Surgery</name>
      <address>
        <city>Bath</city>
        <zip>BA2 3HT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avondale Surgery</name>
      <address>
        <city>Chesterfield</city>
        <zip>S40 4TE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital &amp; Warwickshire -</name>
      <address>
        <city>Coventry</city>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>County Durham &amp; Darlington NHS Foundation Trust</name>
      <address>
        <city>Durham</city>
        <zip>DH1 5GA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Burbage Surgery</name>
      <address>
        <city>Hinckley</city>
        <zip>LE10 2SE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Townhead Research</name>
      <address>
        <city>Irvine</city>
        <zip>KA12 0AY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sherbourne Medical Centre</name>
      <address>
        <city>Leamington Spa</city>
        <zip>CV32 4RA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wythenshawe Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2010</study_first_submitted>
  <study_first_submitted_qc>June 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2010</study_first_posted>
  <results_first_submitted>August 29, 2014</results_first_submitted>
  <results_first_submitted_qc>August 29, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 9, 2014</results_first_posted>
  <last_update_submitted>March 4, 2015</last_update_submitted>
  <last_update_submitted_qc>March 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Constipation</keyword>
  <keyword>Male</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PLACEBO</title>
          <description>Placebo matched to Prucalopride tablet orally once daily.</description>
        </group>
        <group group_id="P2">
          <title>PRUCALOPRIDE</title>
          <description>Prucalopride 2 milligram (mg) tablet orally once daily for subjects greater than or equal to (≥) 18 to less than (&lt;) 65 years; 1 mg once daily orally for subjects ≥65 years, and in case of insufficient response, increased to 2 mg once daily orally at Week 2 or Week 4.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="187"/>
                <participants group_id="P2" count="187"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="160"/>
                <participants group_id="P2" count="158"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Subject Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Non-Compliant</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Principal investigator left hospital</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Selection criteria not met</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor's Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Too busy, no time for study</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Went on holiday</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Colonoscopy result</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Safety Population included all subjects randomized into the study and who took at least 1 dose of investigational product (n = 370).</population>
      <group_list>
        <group group_id="B1">
          <title>PLACEBO</title>
          <description>Placebo matched to Prucalopride tablet orally once daily.</description>
        </group>
        <group group_id="B2">
          <title>PRUCALOPRIDE</title>
          <description>Prucalopride 2 mg tablet orally once daily for subjects ≥18 to &lt;65 years; 1 mg once daily orally for subjects ≥65 years, and in case of insufficient response, increased to 2 mg once daily orally at Week 2 or Week 4.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="186"/>
            <count group_id="B2" value="184"/>
            <count group_id="B3" value="370"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.5" spread="16.28"/>
                    <measurement group_id="B2" value="58.4" spread="17.57"/>
                    <measurement group_id="B3" value="58.5" spread="16.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Less than 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 65 and 75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>75 years and above</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="186"/>
                    <measurement group_id="B2" value="184"/>
                    <measurement group_id="B3" value="370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>BELGIUM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BULGARIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CZECH REPUBLIC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENMARK</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRANCE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GERMANY</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NETHERLANDS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>POLAND</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ROMANIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UNITED KINGDOM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Subjects With an Average of ≥3 Spontaneous Complete Bowel Movements (SCBM) Per Week</title>
        <description>Spontaneous Bowel Movements defined as a bowel movement that is not preceded within a period of 24 hours by the intake of a laxative agent or by the use of an enema.</description>
        <time_frame>Over 12 week treatment period</time_frame>
        <population>Modified Intent-to-treat Population (mITT) included all subjects randomized into the study except those excluded due to a major good clinical practice (GCP) breach at one site, who took at least 1 dose of the investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo matched to Prucalopride tablet orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>PRUCALOPRIDE</title>
            <description>Prucalopride 2 mg tablet orally once daily for subjects ≥18 to &lt;65 years; 1 mg once daily orally for subjects ≥65 years, and in case of insufficient response, increased to 2 mg once daily orally at Week 2 or Week 4.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Subjects With an Average of ≥3 Spontaneous Complete Bowel Movements (SCBM) Per Week</title>
          <description>Spontaneous Bowel Movements defined as a bowel movement that is not preceded within a period of 24 hours by the intake of a laxative agent or by the use of an enema.</description>
          <population>Modified Intent-to-treat Population (mITT) included all subjects randomized into the study except those excluded due to a major good clinical practice (GCP) breach at one site, who took at least 1 dose of the investigational product.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
                <count group_id="O2" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.7"/>
                    <measurement group_id="O2" value="37.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With an Average Weekly Frequency of at Least 3 SCBM Per Week and an Increase of ≥ 1 SCBM Per Week for ≥ 75% of the 12-week Treatment Period and ≥ 75% of the Last Third of the 12-week Treatment Period</title>
        <time_frame>Over 12 week treatment period</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo matched to Prucalopride tablet orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>PRUCALOPRIDE</title>
            <description>Prucalopride 2 mg tablet orally once daily for subjects ≥18 to &lt;65 years; 1 mg once daily orally for subjects ≥65 years, and in case of insufficient response, increased to 2 mg once daily orally at Week 2 or Week 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With an Average Weekly Frequency of at Least 3 SCBM Per Week and an Increase of ≥ 1 SCBM Per Week for ≥ 75% of the 12-week Treatment Period and ≥ 75% of the Last Third of the 12-week Treatment Period</title>
          <population>mITT</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
                <count group_id="O2" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2"/>
                    <measurement group_id="O2" value="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With an Increase of at Least 1 SCBM Per Week</title>
        <time_frame>Over 12 week treatment period</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo matched to Prucalopride tablet orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>PRUCALOPRIDE</title>
            <description>Prucalopride 2 mg tablet orally once daily for subjects ≥18 to &lt;65 years; 1 mg once daily orally for subjects ≥65 years, and in case of insufficient response, increased to 2 mg once daily orally at Week 2 or Week 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With an Increase of at Least 1 SCBM Per Week</title>
          <population>mITT</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
                <count group_id="O2" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.3"/>
                    <measurement group_id="O2" value="53.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SCBM Per Week</title>
        <time_frame>Over 12 week treatment period</time_frame>
        <population>mITT. Not all subjects in the mITT population had data for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo matched to Prucalopride tablet orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>PRUCALOPRIDE</title>
            <description>Prucalopride 2 mg tablet orally once daily for subjects ≥18 to &lt;65 years; 1 mg once daily orally for subjects ≥65 years, and in case of insufficient response, increased to 2 mg once daily orally at Week 2 or Week 4.</description>
          </group>
        </group_list>
        <measure>
          <title>SCBM Per Week</title>
          <population>mITT. Not all subjects in the mITT population had data for this outcome.</population>
          <units>SCBM/week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="1.91"/>
                    <measurement group_id="O2" value="2.6" spread="2.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent SBM With a Consistency of Normal and Hard/Very Hard</title>
        <description>Consistency measured using the 7-point Bristol scale where 1-2 indicate constipation (=hard/very hard), 3-4 are ideal stools (=normal), and 5-7 tending toward diarrhea.</description>
        <time_frame>Over 12 week treatment period</time_frame>
        <population>mITT. Not all subjects in the mITT population had data for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo matched to Prucalopride tablet orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>PRUCALOPRIDE</title>
            <description>Prucalopride 2 mg tablet orally once daily for subjects ≥18 to &lt;65 years; 1 mg once daily orally for subjects ≥65 years, and in case of insufficient response, increased to 2 mg once daily orally at Week 2 or Week 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent SBM With a Consistency of Normal and Hard/Very Hard</title>
          <description>Consistency measured using the 7-point Bristol scale where 1-2 indicate constipation (=hard/very hard), 3-4 are ideal stools (=normal), and 5-7 tending toward diarrhea.</description>
          <population>mITT. Not all subjects in the mITT population had data for this outcome.</population>
          <units>percentage of SBM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
                <count group_id="O2" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Normal consistency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.8" spread="30.21"/>
                    <measurement group_id="O2" value="47.5" spread="31.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hard/Very hard consistency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.9" spread="29.86"/>
                    <measurement group_id="O2" value="26.9" spread="28.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent SCBM With No Straining and Severe/Very Severe Straining</title>
        <description>Straining was evaluated on a 5-point scale (0=none, 1=mild, 2=moderate, 3=severe, or 4=very severe)</description>
        <time_frame>Over 12 week treatment period</time_frame>
        <population>mITT. Not all subjects in the mITT population had data for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo matched to Prucalopride tablet orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>PRUCALOPRIDE</title>
            <description>Prucalopride 2 mg tablet orally once daily for subjects ≥18 to &lt;65 years; 1 mg once daily orally for subjects ≥65 years, and in case of insufficient response, increased to 2 mg once daily orally at Week 2 or Week 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent SCBM With No Straining and Severe/Very Severe Straining</title>
          <description>Straining was evaluated on a 5-point scale (0=none, 1=mild, 2=moderate, 3=severe, or 4=very severe)</description>
          <population>mITT. Not all subjects in the mITT population had data for this outcome.</population>
          <units>percentage of SBM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
                <count group_id="O2" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No straining</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" spread="16.23"/>
                    <measurement group_id="O2" value="9.7" spread="17.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe/Very severe straining</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.7" spread="27.62"/>
                    <measurement group_id="O2" value="20.6" spread="27.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent SBM With Sensation of Complete Evacuation</title>
        <time_frame>Over 12 week treatment period</time_frame>
        <population>mITT. Not all subjects in the mITT population had data for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo matched to Prucalopride tablet orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>PRUCALOPRIDE</title>
            <description>Prucalopride 2 mg tablet orally once daily for subjects ≥18 to &lt;65 years; 1 mg once daily orally for subjects ≥65 years, and in case of insufficient response, increased to 2 mg once daily orally at Week 2 or Week 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent SBM With Sensation of Complete Evacuation</title>
          <population>mITT. Not all subjects in the mITT population had data for this outcome.</population>
          <units>percentage of SBM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
                <count group_id="O2" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.2" spread="32.90"/>
                    <measurement group_id="O2" value="46.7" spread="34.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First SCBM After Investigational Product Intake on Day 1</title>
        <time_frame>Day 1</time_frame>
        <population>mITT.</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo matched to Prucalopride tablet orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>PRUCALOPRIDE</title>
            <description>Prucalopride 2 mg tablet orally once daily for subjects ≥18 to &lt;65 years; 1 mg once daily orally for subjects ≥65 years, and in case of insufficient response, increased to 2 mg once daily orally at Week 2 or Week 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First SCBM After Investigational Product Intake on Day 1</title>
          <population>mITT.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
                <count group_id="O2" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218.9" lower_limit="143.93" upper_limit="291.43"/>
                    <measurement group_id="O2" value="110.3" lower_limit="70.8" upper_limit="172.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bisacodyl Tablets Taken Per Week</title>
        <time_frame>Over 12 week treatment period</time_frame>
        <population>mITT. Not all subjects in the mITT population had data for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo matched to Prucalopride tablet orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>PRUCALOPRIDE</title>
            <description>Prucalopride 2 mg tablet orally once daily for subjects ≥18 to &lt;65 years; 1 mg once daily orally for subjects ≥65 years, and in case of insufficient response, increased to 2 mg once daily orally at Week 2 or Week 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Bisacodyl Tablets Taken Per Week</title>
          <population>mITT. Not all subjects in the mITT population had data for this outcome.</population>
          <units>Tablets/week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="1.76"/>
                    <measurement group_id="O2" value="0.6" spread="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days With Rescue Medication Taken Per Week</title>
        <time_frame>Over 12 week treatment period</time_frame>
        <population>mITT. Not all subjects in the mITT population had data for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo matched to Prucalopride tablet orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>PRUCALOPRIDE</title>
            <description>Prucalopride 2 mg tablet orally once daily for subjects ≥18 to &lt;65 years; 1 mg once daily orally for subjects ≥65 years, and in case of insufficient response, increased to 2 mg once daily orally at Week 2 or Week 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Days With Rescue Medication Taken Per Week</title>
          <population>mITT. Not all subjects in the mITT population had data for this outcome.</population>
          <units>Days/week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.94"/>
                    <measurement group_id="O2" value="0.3" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Subjects With an Improvement of ≥ 1 Point on the Patient Assessment of Constipation – Symptom (PAC-SYM) Questionnaire Total Score at Final On Treatment Assessment</title>
        <description>The PAC-SYM is a validated 12-item questionnaire for the evaluation of severity of symptoms of constipation in subjects with constipation. Items are rated on a 5-point Likert scale: 0=absent, 1=mild, 2=moderate, 3=severe, 4=very severe. Total score ranges from 0 to 48. Lower scores indicate improvement in symptoms. A 1-point improvement in PAC-SYM total score was considered clinically meaningful.</description>
        <time_frame>Over 12 week treatment period</time_frame>
        <population>mITT. Not all subjects in the mITT population had data for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo matched to Prucalopride tablet orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>PRUCALOPRIDE</title>
            <description>Prucalopride 2 mg tablet orally once daily for subjects ≥18 to &lt;65 years; 1 mg once daily orally for subjects ≥65 years, and in case of insufficient response, increased to 2 mg once daily orally at Week 2 or Week 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects With an Improvement of ≥ 1 Point on the Patient Assessment of Constipation – Symptom (PAC-SYM) Questionnaire Total Score at Final On Treatment Assessment</title>
          <description>The PAC-SYM is a validated 12-item questionnaire for the evaluation of severity of symptoms of constipation in subjects with constipation. Items are rated on a 5-point Likert scale: 0=absent, 1=mild, 2=moderate, 3=severe, 4=very severe. Total score ranges from 0 to 48. Lower scores indicate improvement in symptoms. A 1-point improvement in PAC-SYM total score was considered clinically meaningful.</description>
          <population>mITT. Not all subjects in the mITT population had data for this outcome.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="171"/>
                <count group_id="O2" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.4"/>
                    <measurement group_id="O2" value="34.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Subjects With an Improvement of ≥ 1 Point on the Patient Assessment of Constipation - Quality of Life (PAC-QOL) Total Score at Final On Treatment Assessment</title>
        <description>The PAC-QOL is a validated 28-item questionnaire for the evaluation of quality of life in subjects with constipation. Items are rated on a 5-point Likert scale: 0=not at all/none of the time, 1=a little bit/a little bit of the time, 2=moderately/some of the time, 3=quite a bit/most of the time, 4=extremely/all of the time. Total score ranges from 0-112. Lower scores indicate improvement in symptoms. A 1-point improvement in PAC-QOL total score was considered clinically meaningful.</description>
        <time_frame>Over 12 week treatment period</time_frame>
        <population>mITT. Not all subjects in the mITT population had data for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo matched to Prucalopride tablet orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>PRUCALOPRIDE</title>
            <description>Prucalopride 2 mg tablet orally once daily for subjects ≥18 to &lt;65 years; 1 mg once daily orally for subjects ≥65 years, and in case of insufficient response, increased to 2 mg once daily orally at Week 2 or Week 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects With an Improvement of ≥ 1 Point on the Patient Assessment of Constipation - Quality of Life (PAC-QOL) Total Score at Final On Treatment Assessment</title>
          <description>The PAC-QOL is a validated 28-item questionnaire for the evaluation of quality of life in subjects with constipation. Items are rated on a 5-point Likert scale: 0=not at all/none of the time, 1=a little bit/a little bit of the time, 2=moderately/some of the time, 3=quite a bit/most of the time, 4=extremely/all of the time. Total score ranges from 0-112. Lower scores indicate improvement in symptoms. A 1-point improvement in PAC-QOL total score was considered clinically meaningful.</description>
          <population>mITT. Not all subjects in the mITT population had data for this outcome.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="171"/>
                <count group_id="O2" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.7"/>
                    <measurement group_id="O2" value="40.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Subjects on the Subject Global Evaluation on Severity of Constipation Score Rating Constipation as Severe to Very Severe at Final On-Treatment Assessment</title>
        <description>Subject was asked to rate the severity of his constipation using a 5-point Likert scale: 0=absent, 1=mild, 2=moderate, 3=severe, 4=very severe</description>
        <time_frame>Over 12 week treatment period</time_frame>
        <population>mITT. Not all subjects in the mITT population had data for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo matched to Prucalopride tablet orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>PRUCALOPRIDE</title>
            <description>Prucalopride 2 mg tablet orally once daily for subjects ≥18 to &lt;65 years; 1 mg once daily orally for subjects ≥65 years, and in case of insufficient response, increased to 2 mg once daily orally at Week 2 or Week 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects on the Subject Global Evaluation on Severity of Constipation Score Rating Constipation as Severe to Very Severe at Final On-Treatment Assessment</title>
          <description>Subject was asked to rate the severity of his constipation using a 5-point Likert scale: 0=absent, 1=mild, 2=moderate, 3=severe, 4=very severe</description>
          <population>mITT. Not all subjects in the mITT population had data for this outcome.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="171"/>
                <count group_id="O2" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.4"/>
                    <measurement group_id="O2" value="21.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Subjects on the Subject Global Evaluation on Efficacy of Treatment Score Rating Treatment as Quite a Bit to Extremely Effective at Final On-Treatment Assessment</title>
        <description>The subject was asked to rate his global evaluation of the efficacy of treatment using the following 5-point scale:
0=not at all effective
a little bit effective
moderately effective
quite a bit effective
extremely effective.</description>
        <time_frame>Over 12 week treatment period</time_frame>
        <population>mITT. Not all subjects in the mITT population had data for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Placebo matched to Prucalopride tablet orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>PRUCALOPRIDE</title>
            <description>Prucalopride 2 mg tablet orally once daily for subjects ≥18 to &lt;65 years; 1 mg once daily orally for subjects ≥65 years, and in case of insufficient response, increased to 2 mg once daily orally at Week 2 or Week 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects on the Subject Global Evaluation on Efficacy of Treatment Score Rating Treatment as Quite a Bit to Extremely Effective at Final On-Treatment Assessment</title>
          <description>The subject was asked to rate his global evaluation of the efficacy of treatment using the following 5-point scale:
0=not at all effective
a little bit effective
moderately effective
quite a bit effective
extremely effective.</description>
          <population>mITT. Not all subjects in the mITT population had data for this outcome.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="171"/>
                <count group_id="O2" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.4"/>
                    <measurement group_id="O2" value="46.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>PLACEBO</title>
          <description>Placebo matched to Prucalopride tablet orally once daily.</description>
        </group>
        <group group_id="E2">
          <title>PRUCALOPRIDE</title>
          <description>Prucalopride 2 mg tablet orally once daily for subjects ≥18 to less than &lt;65 years; 1 mg once daily orally for subjects ≥65 years, and in case of insufficient response, increased to 2 mg once daily orally at Week 2 or Week 4.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL ISCHAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>LOWER LIMB FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>GLOTTIS CARCINOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ATELECTASIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="186"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="186"/>
                <counts group_id="E2" events="16" subjects_affected="12" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="186"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="186"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Physician</name_or_title>
      <organization>Shire</organization>
      <phone>+1 866 842 5335</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

